A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Melanoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 633 (final count)
- Started
- Nov 2, 2023
- Main results expected
- Jan 25, 2028
- Fully finished
- Jan 25, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response by Week 49
Measured over: Week 49
Objective response at Week 17
Measured over: Week 17
Progression-free survival (PFS)
Measured over: From Randomization until Follow-up or End of treatment (EOT) or Early termination (ET) (Approximately 105 Weeks)
Overall survival (OS)
Measured over: From Randomization until Follow-up or EOT or ET (Approximately 105 Weeks)
Duration of response (DOR)
Measured over: From Randomization until Follow-up or EOT or ET (Approximately 105 Weeks)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06054555 · record last updated 2026-01-12 · checked 2026-11-09 15:47 UTC